<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Cancer Urology</journal-id><journal-title-group><journal-title xml:lang="en">Cancer Urology</journal-title><trans-title-group xml:lang="ru"><trans-title>Онкоурология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9776</issn><issn publication-format="electronic">1996-1812</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1898</article-id><article-id pub-id-type="doi">10.17650/1726-9776-2025-21-1-107-111</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CLINICAL NOTES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Organ-sparing treatment of kidney cancer in the context of autosomal dominant polycystic kidney disease</article-title><trans-title-group xml:lang="ru"><trans-title>Органосохраняющее лечение рака почки на фоне аутосомно-доминантной поликистозной болезни почек</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pozharytski</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Пожарицкий</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>Aliaksandr Mikhailovich Pozharytski - Doctor of the oncourology department of the N.N. Alexandrov RSPC of Oncology and Medical Radiology.</p><p>2 Lesnoy Minsk District 223040</p></bio><bio xml:lang="ru"><p>Александр Михайлович Пожарицки - Врач онкологического урологического отделения РНПЦ ОМР им. Н.Н. Александрова.</p><p>223040 Минский район, п. Лесной, 2</p></bio><email>djshema46@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9811-6591</contrib-id><name-alternatives><name xml:lang="en"><surname>Rolevich</surname><given-names>A. I.</given-names></name><name xml:lang="ru"><surname>Ролевич</surname><given-names>А. И.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>2 Lesnoy Minsk District 223040</p></bio><bio xml:lang="ru"><p>223040 Минский район, п. Лесной, 2</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0006-3712-8405</contrib-id><name-alternatives><name xml:lang="en"><surname>Suslov</surname><given-names>L. N.</given-names></name><name xml:lang="ru"><surname>Суслов</surname><given-names>Л. Н.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>2 Lesnoy Minsk District 223040</p></bio><bio xml:lang="ru"><p>223040 Минский район, п. Лесной, 2</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ryabcheuski</surname><given-names>A. N.</given-names></name><name xml:lang="ru"><surname>Рябчевский</surname><given-names>А. Н.</given-names></name></name-alternatives><address><country country="BY">Belarus</country></address><bio xml:lang="en"><p>2 Lesnoy Minsk District 223040</p></bio><bio xml:lang="ru"><p>223040 Минский район, п. Лесной, 2</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Alexandrov Republican Scientific and Practical Center of Oncology and Medical Radiology</institution></aff><aff><institution xml:lang="ru">ГУ «Республиканский научно-практический центр онкологии и медицинской радиологии им. Н.Н. Александрова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-05-09" publication-format="electronic"><day>09</day><month>05</month><year>2025</year></pub-date><volume>21</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>107</fpage><lpage>111</lpage><history><date date-type="received" iso-8601-date="2025-02-25"><day>25</day><month>02</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-03-25"><day>25</day><month>03</month><year>2025</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://oncourology.abvpress.ru/oncur/article/view/1898">https://oncourology.abvpress.ru/oncur/article/view/1898</self-uri><abstract xml:lang="en"><p>Autosomal dominant polycystic kidney disease is the most common hereditary kidney disease, but the combination of this pathology with renal cell carcinoma is a rare clinical observation. The main treatment method in this situation is nephrectomy. The article presents a clinical case of a 69-year-old patient diagnosed with left kidney cancer  pT1bN0M0, stage I with autosomal dominant polycystic kidney disease and chronic kidney disease. Due to severe concomitant kidney pathology, the patient underwent organ-preserving surgery in November of 2024 which included resection of the left kidney with fenestration and excision of renal cysts. The early and late postoperative periods were uneventful with preservation of renal function.</p></abstract><trans-abstract xml:lang="ru"><p>Аутосомно-доминантная поликистозная болезнь почек занимает 1-е место по распространенности среди наследственных заболеваний почек, однако сочетание данной патологии с почечно-клеточным раком является достаточно редким клиническим наблюдением. Главным методом лечения в подобной ситуации является нефрэктомия. В статье представлен клинический случай пациента 69 лет с диагнозом рака левой почки pT1bN0M0, I стадия, на фоне аутосомно-доминантной поликистозной болезни почек и хронической болезни почек. По причине выраженной сопутствующей патологии почек пациенту в ноябре 2024 г. выполнено органосохраняющее хирургическое лечение в объеме резекции левой почки с фенестрацией и иссечением почечных кист. Течение раннего и позднего послеоперационных периодов без осложнений и с сохранением почечной функции.</p></trans-abstract><kwd-group xml:lang="en"><kwd>autosomal dominant polycystic kidney disease</kwd><kwd>clear cell renal cell carcinoma</kwd><kwd>organ-sparing treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>аутосомно-доминантная поликистозная болезнь почек</kwd><kwd>светлоклеточный почечно-клеточный рак</kwd><kwd>органосохраняющее лечение</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The work was performed without external funding</funding-statement><funding-statement xml:lang="ru">Работа выполнена без спонсорской поддержки</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Hansen C., Derrick M., Warriach I. et al. The association between autosomal dominant polycystic kidney disease and renal cell carcinoma. Open Journal of Urology. 2021;5:84–90. DOI: 10.4236/oju.2015.56013</mixed-citation><mixed-citation xml:lang="ru">Hansen C., Derrick M., Warriach I. et al. The association between autosomal dominant polycystic kidney disease and renal cell carcinoma. Open J Urol 2021;5:84–90. DOI: 10.4236/oju.2015.56013</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Bergmann C., Guay-Woodford L., Harris P.C. et al. Polycystic kidney disease. Nat Rev Dis Primers. 2018;4(1):50-58. DOI: 10.1038/s41572-018-0047-y</mixed-citation><mixed-citation xml:lang="ru">Bergmann C., Guay-Woodford L., Harris P.C. et al. Polycystic kidney disease. Nat Rev Dis Primers 2018;4(1):50–8. DOI: 10.1038/s41572-018-0047-y</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Hajj P., Ferlicot S., Massoud W. et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology. 2009;74(3):631–634. DOI: 10.1016/j.urology.2009.02.078</mixed-citation><mixed-citation xml:lang="ru">Hajj P., Ferlicot S., Massoud W. et al. Prevalence of renal cell carcinoma in patients with autosomal dominant polycystic kidney disease and chronic renal failure. Urology 2009;74(3):631–4. DOI: 10.1016/j.urology.2009.02.078</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Jilg C.A., Drendel V., Bacher J. et al. Autosomal dominant polycystic kidney disease: prevalence of renal neoplasias in surgical kidney specimens. Nephron Clin Pract. 2013;123:13–21. DOI: 10.1159/000351049</mixed-citation><mixed-citation xml:lang="ru">Jilg C.A., Drendel V., Bacher J. et al. Autosomal dominant polycystic kidney disease: prevalence of renal neoplasias in surgical kidney specimens. Nephron Clin Pract 2013;123:13–21. DOI: 10.1159/000351049</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Grantham J., Torres V., Chapman A. et al. The importance of total kidney volume in evaluating progression of polycystic kidney disease. N Engl J Med. 2006;354(20):2122–30. DOI: 10.1056/NEJMoa054341</mixed-citation><mixed-citation xml:lang="ru">Vias P., Goyal S., Madan R. et al. Renal cell carcinoma in the background of autosomal dominant polycystic kidney disease: report of two cases and review of literature. Indian J Med Paediatr Oncol 2023. DOI: 10.1055/s-0043-57268</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Parfrey P.S., Bear J.C., Morgan J. et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med. 2018;323(16):1085-90. DOI: 10.1056/NEJM199010183231601</mixed-citation><mixed-citation xml:lang="ru">Grantham J., Torres V., Chapman A. et al. The importance of total kidney volume in evaluating progression of polycystic kidney disease. N Engl J Med 2006;354(20):2122–30. DOI: 10.1056/NEJMoa054341</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Vias P., Goyal S., Madan R. et al. Renal cell carcinoma in the background of autosomal dominant polycystic kidney disease: report of two cases and review of literature. Indian J Med Paediatr Oncol. 2023:0–5. DOI: 10.1055/s-0043-57268</mixed-citation><mixed-citation xml:lang="ru">Parfrey P.S., Bear J.C., Morgan J. et al. The diagnosis and prognosis of autosomal dominant polycystic kidney disease. N Engl J Med 2018;323(16):1085–90. DOI: 10.1056/NEJM199010183231601</mixed-citation></citation-alternatives></ref></ref-list></back></article>
